Claim check
Common marketing claims, each matched with a condensed version of what the cited sources on the compound page support.
This is a source-check index of common marketing claims, ordered by how many claims each compound page covers. It is not a debunk gallery, and it is not use advice.
Showing 412 of 412 claims
“SS-31 is FDA-approved.”
What the sources say: Plainly: Forzinity is approved for Barth syndrome muscle strength. A research vial, compounded product, clinic protocol, or off-label use has to be judged on its own evidence. Full breakdown
“SS-31 improves fatigue and walking capacity in Barth syndrome.”
What the sources say: The approved-product claim is muscle strength. Fatigue and walking-capacity claims are weaker because the randomized period did not show the same clear separation, and the confirmatory trial is still part of the… Full breakdown
“SS-31 works for primary mitochondrial myopathy.”
What the sources say: After MMPOWER-3, PMM reads as a research area rather than a broad treatment claim. Genotype-specific and NuPOWER findings remain narrower hypotheses built from registry, post hoc, or company-reported sources. Full breakdown
“SS-31 may help selected mitochondrial genotypes.”
What the sources say: A real research lead, but not a reason to assume SS-31 treats every mitochondrial condition. Full breakdown
“SS-31 is an investigational therapy for dry AMD or LHON.”
What the sources say: The AMD and LHON data keep elamipretide in ophthalmology research: early visual-function, retinal-structure, and topical-safety signals, but no approved vision-restoration use. Full breakdown
“SS-31 helps heart failure or cardioprotection.”
What the sources say: The heart-failure data are mixed, and the larger multiple-dose structural endpoint missed. That leaves a narrow research summary, not an established heart-failure treatment claim. Full breakdown
“SS-31 may protect kidneys during renal revascularization.”
What the sources say: This belongs as a pilot-study finding. It is not a broad kidney-health or renal-repair claim. Full breakdown
“SS-31 is an anti-aging, longevity, recovery, or energy peptide.”
What the sources say: People discuss or report using SS-31 for energy, recovery, and longevity goals. The support is mechanism, clinic pages, and reports rather than human anti-aging outcomes. Full breakdown
“SS-31 helps ME/CFS or long COVID fatigue.”
What the sources say: These are anecdotes, not ME/CFS or long-COVID trials. Many reports stack SS-31 with MOTS-c, BPC-157, breathwork, hyperbaric oxygen, Selank, CBD, NAD/NR, pacing, or diet changes, so it is hard to know how much credit to… Full breakdown
“SS-31 supports weight loss or fat loss.”
What the sources say: Weight loss is a weak fit for SS-31. In metabolic discussion, it fits better as mitochondrial context than as a fat-loss peptide. Full breakdown
“A vendor COA shows injectable quality.”
What the sources say: A COA can be a limited quality clue. It is still a long way from a gray-market vial to Forzinity-level product control. Full breakdown
“Online SS-31 schedules set a practical dosing standard.”
What the sources say: This pattern circulates online as a market schedule, not label dosing or controlled-trial exposure. Full breakdown
“Thymosin alpha-1 boosts the immune system.”
What the sources say: Plausible immune biology, but the human data are tied to specific conditions and study designs. Full breakdown
“It helps chronic hepatitis B.”
What the sources say: The hepatitis B claim can be made for older chronic hepatitis B and Zadaxin contexts. That does not create current U.S. approval language or a general viral-illness use. Full breakdown
“It reduces sepsis mortality.”
What the sources say: Not a general sepsis-benefit claim after the current phase 3 result. Full breakdown
“It treats or prevents COVID-19.”
What the sources say: A research and anecdote topic, not an established COVID treatment or prevention use. Full breakdown
“It improves vaccine response.”
What the sources say: Positive evidence in selected groups, but not a general vaccine-upgrade claim. Full breakdown
“It helps cancer treatment.”
What the sources say: Oncology-adjacent and investigational, with no broad cancer-treatment conclusion from thymosin alpha-1 sources. Full breakdown
“It helps Lyme, MCAS, ME/CFS, EBV, hair loss, anti-aging, or general wellness.”
What the sources say: These are documented search and clinic-use themes, but support for each one depends on condition-specific human data. Full breakdown
“What can a COA tell you about injectable thymosin alpha-1?”
What the sources say: A COA is only one piece. Identity, impurities, aggregates, sterility, endotoxin, concentration, solubility, storage, and chain of custody all matter. Full breakdown
“Chonluten is a respiratory peptide.”
What the sources say: Respiratory discussion is real in the sources. The jump from respiratory bioregulator to reliable treatment for lung disease is the part the evidence does not yet support. Full breakdown
“Chonluten has anti-inflammatory effects.”
What the sources say: The THP-1 findings show immune-cell signaling changes in the lab. Reduced inflammation in people would need human outcome data. Full breakdown
“Chonluten treats COPD, asthma, chronic bronchitis, pneumonia, or ARDS.”
What the sources say: This remains a weakly documented claim with missing primary human evidence, not a demonstrated treatment effect. Full breakdown
“Chonluten supports gastric or mucosal repair.”
What the sources say: This remains preclinical and product-claim context unless stronger human evidence is added. Full breakdown
“Chonluten is a longevity or anti-aging peptide.”
What the sources say: This is mostly marketing and family-level extrapolation, not a human longevity claim. Full breakdown
“Chonluten is a mitochondrial peptide.”
What the sources say: The Chonluten evidence does not back a mitochondrial claim. Full breakdown
“A Chonluten COA confirms product identity and injectable quality.”
What the sources say: A COA can be a clue, but it does not resolve Chonluten's identity and injectable-quality questions. Full breakdown
“GHRP-2 raises growth hormone.”
What the sources say: Supported for acute GH provocation. Muscle, fat-loss, recovery, and anti-aging claims are separate outcome claims. Full breakdown
“GHRP-2 is an accepted diagnostic test for growth hormone deficiency.”
What the sources say: Supported as diagnostic use, especially in Japan. It is not the same as approval for repeated wellness or performance use. Full breakdown
“GHRP-2 increases appetite.”
What the sources say: Supported as an acute human effect. Extra intake is not the same as healthy weight gain, and it cuts against simple fat-loss marketing. Full breakdown
“GHRP-2 builds muscle, improves recovery, or improves performance.”
What the sources say: Common in marketing and user reports, but not backed here by a controlled healthy-adult outcome study. Full breakdown
“GHRP-2 burns fat.”
What the sources say: Fat-loss language is common in marketing, but the cited clinical literature is mainly endocrine and diagnostic context. Full breakdown
“GHRP-2 is selective for growth hormone only.”
What the sources say: Misleading. GHRP-2 is better described as a GH secretagogue with documented endocrine spillover. Full breakdown
“Can seller paperwork show a gray-market GHRP-2 vial matches studied material?”
What the sources say: A COA can be one narrow data point. Reliability still depends on sterile injectable quality, correct concentration, impurity control, and whether the vial is suitable for the claimed route. Full breakdown
“Glutathione raises glutathione levels.”
What the sources say: Partly supported for markers. Broad clinical benefit claims would need stronger outcome data than the marker-focused evidence here. Full breakdown
“Glutathione is an established detox therapy.”
What the sources say: Glutathione chemistry helps explain detox marketing, but the cited human evidence does not prove it works as a broad detox treatment. Full breakdown
“Glutathione lightens skin.”
What the sources say: Narrow oral or topical cosmetic signals can be described, but IV skin whitening remains a high-caution claim with limited support and real harm reports. Full breakdown
“IV glutathione works better because oral glutathione is poorly absorbed.”
What the sources say: Too simple. IV changes exposure, but it also adds sterile-product risk and leaves the marketed outcome unproven. Full breakdown
“Glutathione treats Parkinson's disease.”
What the sources say: Investigational at most. It is not an established Parkinson's therapy. Full breakdown
“Glutathione helps chemotherapy-related neuropathy.”
What the sources say: Mention as a narrow oncology-adjunct research area, not as a general neuropathy, detox, or wellness rationale. Full breakdown
“Liposomal or nano glutathione is automatically superior.”
What the sources say: Product-specific evidence is needed. Liposomal or nano branding is not class-wide clinical evidence. Full breakdown
“Oxytocin is FDA-approved for autism, social anxiety, bonding, libido, or trust.”
What the sources say: The approved product record is obstetric. It does not cover consumer social or neurocognitive use. Full breakdown
“Oxytocin reliably increases trust or bonding.”
What the sources say: Trust and bonding claims are tied to the specific lab task; they do not become a general consumer promise. Full breakdown
“Intranasal oxytocin improves core autism symptoms.”
What the sources say: Worth studying, but not an established autism treatment. Full breakdown
“Oxytocin helps schizophrenia cognition or symptoms.”
What the sources say: Not supported as a broad cognition claim. Full breakdown
“Oxytocin may help apathy in frontotemporal dementia.”
What the sources say: The most notable current neuro finding, but still preliminary. Full breakdown
“Oxytocin is a libido or intimacy enhancer.”
What the sources say: Discussable as a source of demand and small-study interest, not as a settled libido drug. Full breakdown
“What can a vendor COA tell you about an oxytocin nasal spray or vial?”
What the sources say: A COA may be one useful document, while pharmaceutical-grade nasal oxytocin depends on finished-product controls, device performance, sterility, concentration, storage, and lawful manufacturing. Full breakdown
“Thymogen is alpha-glutamyl-tryptophan.”
What the sources say: Alpha-glutamyl-tryptophan is the main identity when the material is talking about that dipeptide. Products carrying the name may still differ by salt form, formulation, or blend. Full breakdown
“Thymogen supports immune function.”
What the sources say: The human findings come from specific products and settings, including perioperative use and chronic atrophic gastritis studies. They do not show that thymogen broadly improves immunity in healthy people. Full breakdown
“Thymogen helps chronic atrophic gastritis.”
What the sources say: This is a narrow human finding, not broad evidence for gut healing, systemic immunity, or anti-aging claims. Full breakdown
“Thymogen prevents colds or treats respiratory infections.”
What the sources say: The evidence consists of regional-label and weak observational context and is too weak to support a broad respiratory-treatment claim. Full breakdown
“Thymogen is an anti-cancer peptide.”
What the sources say: Thymogen is not supported as a cancer therapy. The oncology history is a warning against cancer-treatment marketing, not evidence of benefit. Full breakdown
“Thymogen is an anti-aging or longevity peptide.”
What the sources say: No study in this source set measured lifespan, frailty, or healthy-aging outcomes in people. Full breakdown
“Research vials or blended supplements are equivalent to official Thymogen products.”
What the sources say: Misleading as a shortcut. Product identity and batch documentation have to be checked separately from the molecule's formal literature. Full breakdown
“ARA-290 may help sarcoidosis-associated small-fiber neuropathy.”
What the sources say: Reasonable to discuss as a narrow sarcoidosis small-fiber-neuropathy research finding. Too early to describe as a settled treatment. Full breakdown
“ARA-290 improves diabetic neuropathy or metabolic markers.”
What the sources say: Early human data, not a diabetes-care standard and not a general neuropathy claim. Full breakdown
“ARA-290 is a nerve-regeneration peptide.”
What the sources say: Read this as disease-specific small-fiber research, not as a general nerve-regrowth product. Full breakdown
“ARA-290 is safer than erythropoietin.”
What the sources say: The design rationale is real. Blanket safety claims are too broad. Full breakdown
“ARA-290 works for long COVID, chronic fatigue, autoimmune disease, anti-aging, or general recovery.”
What the sources say: Human studies in sarcoidosis, diabetes, eye disease, and healthy-volunteer settings do not provide enough support for that claim. Full breakdown
“A research-use vial is equivalent to clinical-study cibinetide.”
What the sources say: The molecule name alone is not product evidence. Full breakdown
“BPC-157 heals tendons, ligaments, joints, or soft tissue.”
What the sources say: The recovery claim is worth studying, but the human evidence is still thin. The knee review is a useful clue, not a universal recovery guide. Full breakdown
“BPC-157 helps gut problems or ulcerative colitis.”
What the sources say: A real research theme, but these sources do not back BPC-157 as an ulcerative-colitis or gut-symptom therapy. Full breakdown
“BPC-157 has known safe IV or injectable dosing.”
What the sources say: The two-person IV pilot gives a concrete exposure example, but it is too small to answer repeated IV, subcutaneous, intramuscular, or gray-market product safety. Full breakdown
“Oral BPC-157 works as a gut or recovery protocol.”
What the sources say: The oral trial gives route and amount details, not evidence that oral BPC-157 improves gut symptoms or recovery. Full breakdown
“A research-use or compounded vial is equivalent to studied BPC-157.”
What the sources say: A shared molecule name is not the same as having the studied product. Route-specific evidence has to cover identity, concentration, sterility, endotoxin, impurities, and handling. Full breakdown
“BPC-157 plus TB-500 evidence carries over to standalone BPC-157.”
What the sources say: TB-500 and blend claims are separate from standalone BPC-157 evidence. Full breakdown
“Bronchogen treats COPD, asthma, chronic bronchitis, or long COVID.”
What the sources say: The lung-disease rationale is plausible but thin. The available sources are useful for understanding why people are interested and what product risks matter, not for calling Bronchogen a proven COPD, asthma,… Full breakdown
“Bronchogen supports bronchial epithelial repair.”
What the sources say: Plausible preclinical wording is fair. Human repair or treatment wording needs stronger patient data than the sources provide. Full breakdown
“Bronchogen binds DNA and changes gene expression.”
What the sources say: Mechanism findings should stay tied to the AEDL/ADEL sequence conflict. Full breakdown
“Bronchogen is safe because patents and brochures say it was non-toxic.”
What the sources say: Clinical safety is not well characterized, including human safety, interactions, reproductive risk, long-term exposure, and injected-vial safety. Full breakdown
“A 20 mg research vial is equivalent to the Russian capsule product.”
What the sources say: No. Oral capsules and research vials create different dose, route, and quality questions around Bronchogen. Full breakdown
“A COA confirms pharmaceutical-grade Bronchogen.”
What the sources say: A COA can be a limited clue. It cannot show sterile injectable quality, clinical equivalence, or complete identity control. Full breakdown
“Cartalax is a cartilage peptide.”
What the sources say: The identity and cartilage-research interest are fair, but human cartilage rebuilding goes beyond the evidence. Full breakdown
“Cartalax improves osteoarthritis symptoms.”
What the sources say: The evidence provides a weak historical symptom signal. It is not enough to make Cartalax a confirmed osteoarthritis treatment. Full breakdown
“Cartalax rebuilds or regenerates cartilage in humans.”
What the sources say: The evidence supports cartilage-oriented discussion, not a human cartilage-regeneration claim. Full breakdown
“Cartalax helps osteoporosis or bone health.”
What the sources say: This remains preclinical plus legacy-report context. Bone-density and fracture-risk claims would need better human evidence. Full breakdown
“Cartalax is an anti-aging or longevity peptide.”
What the sources say: The anti-aging claim rests on market discussion and mechanism; a human anti-aging benefit has not been shown. Full breakdown
“Cartalax is safe because legacy reports showed no side effects.”
What the sources say: Short-term tolerability claims are too limited for broad safety language. Route, formulation, sterility, immune response, impurities, and long-term biology remain important unknowns. Full breakdown
“CJC-1295 DAC raises growth hormone and IGF-1.”
What the sources say: The hormone effect is real in small studies. Physique, sleep, recovery, and anti-aging claims are a separate layer of interpretation. Full breakdown
“CJC-1295 DAC burns fat or builds muscle.”
What the sources say: Common in the market and mechanistically plausible, but not a measured CJC-1295 DAC outcome in the cited human studies. Full breakdown
“CJC-1295 DAC improves sleep, recovery, or anti-aging.”
What the sources say: Reasonable to cover as a real-world use theme. The cited human studies, though, are not sleep, recovery, injury-healing, or anti-aging trials. Full breakdown
“CJC-1295 DAC is a growth hormone deficiency treatment.”
What the sources say: The cited sources do not support describing it as a growth hormone deficiency therapy. Full breakdown
“DAC and no-DAC CJC-1295 are interchangeable.”
What the sources say: Keep the names separate before applying any study, protocol, safety, or product-quality statement. Full breakdown
“Can seller paperwork show a CJC-1295 DAC vial matches study material?”
What the sources say: Useful lot evidence has to confirm the right DAC form and cover the injectable-quality questions that matter for that exact batch. Full breakdown
“DSIP is a reliable deep-sleep peptide.”
What the sources say: DSIP is an older insomnia-research peptide with small, mixed human sleep findings, not a dependable deep-sleep tool. Full breakdown
“DSIP improves sleep latency and sleep efficiency.”
What the sources say: Discussable as narrow historical evidence for sleep latency and efficiency, but not a basis for treating DSIP as a broad insomnia treatment. Full breakdown
“DSIP supports recovery.”
What the sources say: Recovery remains an extrapolation from sleep and stress-interest themes because the available sources do not directly test recovery outcomes. Full breakdown
“DSIP or emideltide helps opioid withdrawal or narcolepsy.”
What the sources say: These are high-caution claims. The FDA materials identify proposed uses and safety gaps; they do not show a withdrawal or narcolepsy regimen. Full breakdown
“The 25 nmol/kg study amount can be copied into modern DSIP use.”
What the sources say: The 25 nmol/kg figure applies only to the historical IV studies; it is not a general bedtime, nasal, oral, or injection regimen. Full breakdown
“A DSIP vial labeled with a sequence is equivalent to study DSIP.”
What the sources say: Misleading. Product quality has to be judged separately from molecule name and from old study abstracts. Full breakdown
“GHK-Cu improves wrinkles or skin appearance.”
What the sources say: The evidence supports a modest topical skin-appearance claim. Skin-aging reversal and injectable use need stronger route-specific evidence. Full breakdown
“GHK-Cu helps wounds heal.”
What the sources say: The support is narrow: topical wound and post-procedure use can be discussed, but broad injectable repair claims are not supported by the cited evidence. Full breakdown
“GHK-Cu helps after laser resurfacing or cosmetic procedures.”
What the sources say: The post-laser evidence is mixed and specific to topical aftercare; it does not prove that GHK-Cu reliably speeds recovery. Full breakdown
“GHK-Cu grows hair.”
What the sources say: Hair is a common market use case, but the listed sources do not make the case for standalone GHK-Cu hair regrowth. Full breakdown
“Injectable GHK-Cu is a systemic repair or anti-aging peptide.”
What the sources say: Injectable GHK-Cu lacks direct human support in the cited evidence. For injectable claims, FDA's safety-risk warning is a major part of the answer. Full breakdown
“A copper-peptide cosmetic product is automatically low-risk because it is topical.”
What the sources say: Topical is the better-supported route here, but the exact product and claim still matter. Full breakdown
“GHRP-6 increases growth hormone.”
What the sources say: Supported as an acute endocrine effect. That hormone bump is still not physique, recovery, or anti-aging evidence. Full breakdown
“GHRP-6 builds muscle or improves performance.”
What the sources say: A popular extrapolation from GH-axis biology, not a demonstrated GHRP-6 outcome in the human evidence. Full breakdown
“GHRP-6 burns fat.”
What the sources say: The cited human literature is mainly acute endocrine context, not a fat-loss outcome program. Full breakdown
“GHRP-6 increases appetite.”
What the sources say: Plausible and commonly discussed, but not well quantified as a GHRP-6 clinical outcome in the cited evidence. Full breakdown
“GHRP-6 improves sleep or recovery.”
What the sources say: These studies are useful for endocrine-sleep physiology, but they do not show better sleep or recovery. Full breakdown
“A research-use vial with a COA is equivalent to studied GHRP-6.”
What the sources say: A COA is a narrow analytical document, and clinical-grade injectable quality needs more than that. Full breakdown
“Hexarelin raises growth hormone.”
What the sources say: Supported for short-term GH release in small physiology studies. Those studies did not test muscle, fat-loss, recovery, or anti-aging benefit. Full breakdown
“Hexarelin builds muscle or improves body composition.”
What the sources say: Muscle and body-composition claims remain extrapolations from GH biology, not measured hexarelin outcomes. Full breakdown
“Hexarelin improves sleep or recovery.”
What the sources say: The cited human sleep study argues against calling hexarelin a sleep peptide: it found less slow-wave sleep rather than a sleep benefit. Full breakdown
“Hexarelin improves heart function.”
What the sources say: Exploratory cardiac physiology only. These studies do not make hexarelin a heart treatment. Full breakdown
“Oral hexarelin is a dependable route.”
What the sources say: Oral exposure should stay in the historical route discussion, not in public efficacy claims. Full breakdown
“Hexarelin is safer because it is a peptide or because it releases the body's own GH.”
What the sources say: The safety picture is incomplete. Human endocrine effects and gray-market product risks belong in the same risk discussion. Full breakdown
“HGH Fragment 176-191 is clinically established for fat loss.”
What the sources say: The fat-loss claim runs ahead of the evidence. The direct native fragment human evidence is missing and the related analogue failed to show convincing obesity efficacy. Full breakdown
“HGH Fragment 176-191 is the same as AOD-9604.”
What the sources say: This shorthand is misleading because the molecular relationship does not make the human studies, routes, safety evidence, or product-quality evidence interchangeable. Full breakdown
“Subcutaneous HGH Fragment 176-191 or AOD-9604 is clinically studied for weight loss.”
What the sources say: Subcutaneous use is a current market route, but the available human weight-loss data are oral and IV rather than subcutaneous. Full breakdown
“It burns fat without affecting IGF-1 or glucose.”
What the sources say: Partly grounded in the specific analogue studies, but overbroad when applied to every product, route, or long-term use scenario. Full breakdown
“It repairs cartilage, joints, or soft tissue.”
What the sources say: Repair and recovery claims remain animal or market claims; the available human material does not show benefit. Full breakdown
“What can a COA tell you about vial quality?”
What the sources say: A COA may support a narrow batch claim, but injectable, oral, or topical products still need route-specific quality checks and evidence in people. Full breakdown
“Livagen is a human liver-healing peptide.”
What the sources say: Livagen is liver-associated in preclinical and review literature, but human liver-repair treatment claims go beyond the evidence. Full breakdown
“Livagen reactivates chromatin in aged human cells.”
What the sources say: These studies exposed human lymphocytes outside the body. They show cell-marker movement, not slower aging, better organ function, or symptom improvement in people. Full breakdown
“Livagen inhibits enkephalinase or affects opioid biology.”
What the sources say: The evidence shows an in vitro enzyme interaction, not pain relief, mood effects, opioid activity, or a clinical outcome in people. Full breakdown
“Livagen is an anti-aging or longevity peptide for people.”
What the sources say: Mostly extrapolation. The available work supports a research question, not a clinical longevity claim. Full breakdown
“Livagen is mitochondrial.”
What the sources say: Livagen sometimes gets placed near mitochondrial products, but the cited work does not test mitochondrial endpoints or show a mitochondrial benefit in people. Full breakdown
“Research-use Livagen products are safe because sellers provide COAs or disclaimers.”
What the sources say: Product-quality and regulatory risk are central to any Livagen risk discussion. Full breakdown
“MOTS-c improves insulin sensitivity.”
What the sources say: Worth following, but the key missing evidence is still a posted human outcome from administered MOTS-c. Full breakdown
“MOTS-c supports weight loss or body recomposition.”
What the sources say: MOTS-c remains a metabolic research peptide. Human weight-loss and body-recomposition outcomes have not been shown. Full breakdown
“MOTS-c is a longevity or anti-aging peptide.”
What the sources say: Longevity is a real public claim around MOTS-c, but it has not been shown as a human benefit. Full breakdown
“MOTS-c improves energy, endurance, or exercise adaptation.”
What the sources say: For now, this is market and anecdotal discussion unless direct human intervention data become available. Full breakdown
“Subcutaneous MOTS-c has a standard public schedule.”
What the sources say: The concrete schedule here is the trial-registry pattern. Public schedules outside that trial still need direct support. Full breakdown
“A research-use MOTS-c vial is equivalent to investigational study material.”
What the sources say: No. Product quality has to be checked separately from the molecule's research rationale. Full breakdown
“N-Acetyl Selank Amidate works for anxiety like Selank.”
What the sources say: The anxiety discussion mostly comes from the Selank family. Exact-analog human anxiety and safety data were not found. Full breakdown
“The amidated form crosses the blood-brain barrier better than regular Selank.”
What the sources say: Better brain penetration is a market claim for now. Parent-label pharmacokinetic language does not answer exact-analog brain exposure. Full breakdown
“It lasts longer or is more potent because it is acetylated and amidated.”
What the sources say: Plausible chemistry logic and common seller language, but still not a measured human clinical or pharmacokinetic advantage for this exact analog. Full breakdown
“It is a nootropic for focus, memory, or social calm.”
What the sources say: This is a common online topic, but the cited analog-specific material has not shown a cognitive-enhancement effect. Full breakdown
“It is non-addictive and safer than benzodiazepines.”
What the sources say: Native Selank tolerability language does not automatically transfer to the amidated analog as a long-term safety guarantee. Full breakdown
“A 99% purity COA verifies a current vial or spray.”
What the sources say: A purity number can be useful, but it still leaves key questions unanswered: sterile handling, endotoxin control, peptide-by-mass content, counterion burden, storage, and whether the shipped lot matches the document. Full breakdown
“NAD+ boosts cellular energy.”
What the sources say: Solid as basic biology; thin as a practical benefit claim unless a source names the product, route, dose, population, and measured outcome. Full breakdown
“NAD+ drips or shots are anti-aging therapy.”
What the sources say: The available human data do not include anti-aging outcomes for these products. Full breakdown
“NAD+ detoxes drugs or treats withdrawal.”
What the sources say: This is a common clinic pitch, but the direct support is thin. Full breakdown
“NAD+ improves cognition, brain fog, or mood.”
What the sources say: It can be discussed as an interest area, but it is not an established effect. Full breakdown
“IV NAD+ improves health because it changes metabolites.”
What the sources say: Metabolite shifts are documented; broad clinical benefit is not. Full breakdown
“A COA or purity test makes a NAD+ vial safe for injection.”
What the sources say: A COA may support a batch-level claim, but it does not answer whether an injectable NAD+ product meets sterile compounding controls, endotoxin limits, finished-product testing, or facility oversight. Full breakdown
“Ovagen is EDL, H-Glu-Asp-Leu.”
What the sources say: Treat EDL as the identity when a source explicitly means H-Glu-Asp-Leu. Products sold as "Ovagen" can still point to a different tripeptide or a loose brand name. Full breakdown
“Ovagen regenerates or repairs the liver.”
What the sources say: The narrow version is fair: patent-described liver biology and marketing interest exist. Established human liver repair has not been shown in the reviewed modern sources for Ovagen. Full breakdown
“Ovagen helps hepatitis or cirrhosis.”
What the sources say: Mention this as patent and institute material. Hepatitis or cirrhosis treatment claims need much stronger clinical evidence. Full breakdown
“Ovagen supports kidney function.”
What the sources say: Plausible as a preclinical research topic. These sources do not show it as a human kidney-support therapy. Full breakdown
“Ovagen is an anti-aging, longevity, or mitochondrial peptide.”
What the sources say: Weak and indirect. Discuss gene-expression and preclinical organ-model work, not longevity or mitochondrial enhancement as settled benefits. Full breakdown
“Vendor COAs make Ovagen products reliable.”
What the sources say: A COA only helps with the Ovagen problem when it confirms the right molecule, representative lot, sterility expectations, endotoxin controls, impurities, storage, and chain of custody. Full breakdown
“P21 improves human memory or cognition.”
What the sources say: The cognition evidence is preclinical, not a human nootropic case. Full breakdown
“P21 treats or prevents Alzheimer disease.”
What the sources say: P21 has Alzheimer-like animal-model findings. That does not mean it treats, prevents, or reverses Alzheimer disease in people. Full breakdown
“P21 promotes neurogenesis and synaptic plasticity.”
What the sources say: The support is limited to animal and lab models. Full breakdown
“P21 is safer than CNTF.”
What the sources say: P021 was engineered to avoid some CNTF problems, but human safety has not been established. Full breakdown
“P21 nasal sprays or research vials match the study preparations.”
What the sources say: Sprays and vials sold online have not been shown to match the animal-study preparations or exposures. Full breakdown
“P21 helps stress relief, wound healing, or broad wellness.”
What the sources say: These are seller and search-visible claims, outside the P021 study core. Full breakdown
“Pancragen helps blood sugar or glucose tolerance.”
What the sources say: A limited early finding, not enough support to replace regulated diabetes care. Full breakdown
“Pancragen repairs the pancreas or restores beta cells.”
What the sources say: The cell findings are not pancreas repair, regeneration, or beta-cell restoration evidence in people. Full breakdown
“Pancragen treats chronic pancreatitis.”
What the sources say: Discuss only as weak company-hosted adjunctive evidence, not as an established pancreatitis therapy. Full breakdown
“Pancragen is a weight-loss peptide.”
What the sources say: No useful weight-loss support was found in the reviewed Pancragen sources. Full breakdown
“Pancragen products are all the same.”
What the sources say: A capsule, patent example, and research vial each require product identity, route, and quality evidence before they can be compared. Full breakdown
“Pancragen has a strong safety record.”
What the sources say: Safety confidence is low, especially for gray-market injectable use. Full breakdown
“PT-141 treats acquired, generalized HSDD in premenopausal women.”
What the sources say: Strong when the wording stays tied to Vyleesi, acquired generalized HSDD, premenopausal women, and the studied endpoints. Full breakdown
“PT-141 improves sexual desire and distress.”
What the sources say: Best limited to the studied HSDD population and endpoints. That does not make it a guaranteed arousal, orgasm, relationship, or performance effect. Full breakdown
“PT-141 enhances sexual performance.”
What the sources say: There is direct older human evidence for intranasal erectile-response effects in men, but not a current approval or a basis for a broad performance-enhancement claim. Full breakdown
“PT-141 is for men.”
What the sources say: PT-141 has direct controlled male erectile-function evidence, but no current male approval. Full breakdown
“PT-141 is a bodybuilding, wellness, mood, or tanning peptide.”
What the sources say: People will see PT-141 in those conversations, but Vyleesi evidence does not show those benefits. Full breakdown
“A PT-141 vial, nasal spray, or oral product is equivalent to Vyleesi.”
What the sources say: Vyleesi evidence stays with the autoinjector, route, dose, storage, and adverse-event system described in the label. Full breakdown
“Selank helps anxiety.”
What the sources say: Small Russian anxiety studies and label history support anxiety-context discussion. Full breakdown
“Selank improves focus, memory, cognition, or brain fog.”
What the sources say: Cognition remains a secondary claim. The biology is plausible, but the human evidence is too limited to call Selank a nootropic treatment. Full breakdown
“Selank works like a benzodiazepine without benzodiazepine downsides.”
What the sources say: The available comparator studies do not establish Selank as dependency-free or risk-free. The short-term signals exist, but they do not make Selank a blanket benzodiazepine alternative. Full breakdown
“Selank raises BDNF or improves neuroplasticity.”
What the sources say: This is preclinical mechanism language, not a human BDNF or cognitive-enhancement result. Full breakdown
“Selank boosts immunity.”
What the sources say: The evidence supports mechanism and biomarker discussion, not broad immune-boosting claims without condition-specific human data. Full breakdown
“Selank is FDA-approved or standard U.S. peptide therapy.”
What the sources say: Not for the United States. Any approval language needs to be jurisdiction-specific to Russia. Full breakdown
“Semax helps after ischemic stroke.”
What the sources say: The stroke and rehab papers are worth discussing, but they are too narrow to turn Semax into a general brain-repair peptide. Full breakdown
“Semax improves cognition, focus, attention, or brain fog.”
What the sources say: Focus and brain-fog claims are real search questions, but the clinical claim remains weak. Published route evidence leans intranasal, and subcutaneous cognition claims are still anecdotal or commercial. Full breakdown
“Subcutaneous Semax is more reliable than intranasal Semax.”
What the sources say: This route-superiority claim appears in clinic and forum reports, but direct human support for route superiority in brain-directed outcomes is still missing. Full breakdown
“Semax helps anxiety, mood, or stress resilience.”
What the sources say: Keep mood and anxiety language secondary. It is a common public claim, but the human evidence is stronger for stroke and optic nerve contexts than for mood. Full breakdown
“Semax is helpful for optic nerve disease.”
What the sources say: This is limited human optic nerve disease evidence, not a broad vision, eye-health, or neuroprotection claim. Full breakdown
“A research vial, clinic product, or nasal spray is equivalent to studied Semax.”
What the sources say: That comparison is too broad. Product identity and quality controls matter as much as the route label. Full breakdown
“SHLP2 is a human weight-loss peptide.”
What the sources say: Not established as a human-use claim. The cited evidence is preclinical metabolism plus mixed human biomarker findings. Full breakdown
“SHLP2 improves insulin sensitivity or glucose control.”
What the sources say: Supported as a preclinical research theme, not as a human diabetes or glucose-control therapy. Full breakdown
“SHLP2 is a longevity or anti-aging peptide.”
What the sources say: Relevant to aging biology, but not evidence for a human longevity therapy. Full breakdown
“SHLP2 treats Parkinson's disease.”
What the sources say: This is genetics and model-based neuroprotection research, not evidence for a Parkinson's treatment. Full breakdown
“SHLP2 helps AMD or vision.”
What the sources say: Cell-model interest only, not an AMD or vision treatment claim. Full breakdown
“SHLP2 is clinically safe because it is endogenous.”
What the sources say: Exogenous SHLP2 product safety remains a major unknown. Full breakdown
“Thymalin restores immune balance.”
What the sources say: Plausible in specific regional-label contexts. Too broad when sold as a general immune-reset claim. Full breakdown
“Thymalin is a longevity or anti-aging peptide.”
What the sources say: Exaggerated when stated as established fact. The available human material can explain the longevity interest, but it is not modern longevity-outcome evidence. Full breakdown
“Thymalin improves severe COVID-19 outcomes.”
What the sources say: Narrow positive signal, but not enough for a broad treatment or prevention claim without randomized, replicated clinical evidence. Full breakdown
“Thymalin is just thymulin or thymosin alpha-1 under another name.”
What the sources say: Incorrect as an identity shortcut. Thymalin, thymulin, and thymosin alpha-1 are separate materials. Full breakdown
“What can a gray-market COA tell you about a thymalin vial?”
What the sources say: A COA can describe one tested sample, but by itself it cannot settle thymalin identity or injectable-drug comparability. Full breakdown
“Thymalin has no meaningful safety issues.”
What the sources say: Too broad. The known safety record is incomplete, and injectable product quality is a major part of the risk. Full breakdown
“Vasopressin is FDA-approved for autism, cognition, or social enhancement.”
What the sources say: Not accurate as stated. Approval is for the monitored IV shock product, while brain and social claims remain experimental. Full breakdown
“Vasopressin may help social functioning in autism.”
What the sources say: Early and research-relevant. Too small and incomplete for a clinical treatment claim. Full breakdown
“Vasopressin is a broad memory or nootropic peptide.”
What the sources say: The studies point to task-specific research interest, not a dependable nootropic claim. Full breakdown
“Vasopressin improves sleep.”
What the sources say: A narrow elderly sleep research signal, not a modern sleep-treatment or wellness claim. Full breakdown
“Intranasal vasopressin reliably reaches the brain.”
What the sources say: Possible under some study conditions, but not guaranteed for online or compounded products. Full breakdown
“What can a vendor COA tell you about a vasopressin product?”
What the sources say: A COA can help characterize a sample, while pharmaceutical quality depends on the finished-drug system around that sample. Full breakdown
“Vesugen is a vascular bioregulator.”
What the sources say: Vesugen is vascular-focused, but the available reports are too weak to show that it reliably treats vascular disease. Full breakdown
“Vesugen improves erectile function or penile blood flow.”
What the sources say: A low-certainty investigational signal, not a reliable ED therapy claim. Full breakdown
“Vesugen improves lower-limb circulation.”
What the sources say: Weak and preliminary. The public details do not provide enough sample-size, comparator, adverse-event, and follow-up information for a confident clinical conclusion. Full breakdown
“Vesugen reverses atherosclerosis or normalizes cardiovascular markers.”
What the sources say: That goes well beyond the current evidence. Better human outcomes data would be needed before it could be written confidently. Full breakdown
“Vesugen is a longevity or mitochondrial peptide.”
What the sources say: The evidence supports aging-biology relevance, but human longevity and direct mitochondrial claims lack human outcome or target-engagement data. Full breakdown
“Vesugen is safe or side-effect free.”
What the sources say: Too little is known to call it side-effect free, contraindication free, or low-risk across current product forms. Full breakdown
“VIP is a real anti-inflammatory peptide.”
What the sources say: Fair as mechanism language. Too broad as a clinical efficacy claim unless the claim names the condition, route, dose, duration, and outcome. Full breakdown
“VIP treats CIRS or mold illness.”
What the sources say: Clinics and forums discuss this use, but the public evidence is still mostly open-label, clinic, and anecdotal. Full breakdown
“VIP helps pulmonary hypertension or pulmonary inflammation.”
What the sources say: A legitimate research area with small human findings. It is not a settled respiratory treatment claim. Full breakdown
“Aviptadil was a COVID rescue treatment.”
What the sources say: Later COVID trial results undercut the rescue-treatment story that grew out of early aviptadil interest. Full breakdown
“VIP is already an approved medicine.”
What the sources say: The product and use case matter. Invicorp is erectile-dysfunction context; it does not make VIP a broad immune, lung, CIRS, or nasal-spray therapy. Full breakdown
“Compounded or gray-market VIP can be trusted if it has a COA.”
What the sources say: A COA can be one limited document. For nasal, inhaled, or injectable confidence, concentration, sterility, endotoxin, storage, and delivered-dose details still matter. Full breakdown
“ACE-031 is an established muscle-growth peptide.”
What the sources say: Too broad. The human evidence shows an early lean-mass signal, not a healthy-user muscle-growth or performance benefit. Full breakdown
“ACE-031 improves Duchenne muscular dystrophy function.”
What the sources say: The DMD signal is worth knowing about, but the program stopped before it became an approved treatment or a settled functional-benefit claim. Full breakdown
“ACE-031 is safe because serious adverse events were not reported.”
What the sources say: Misleading if stated broadly. "No serious adverse events in a short early trial" does not mean the safety profile is settled. Full breakdown
“ACE-031 is available as a standard research peptide.”
What the sources say: Insufficient. A seller would need construct identity, protein-impurity, aggregation, sterility, endotoxin, and lot-traceability evidence before the vial could be compared with clinical ACE-031. Full breakdown
“A COA proves a gray-market ACE-031 vial matches clinical ACE-031.”
What the sources say: For ACE-031, no. The best current gray-market evidence says the name on the vial is not reliable. Full breakdown
“Afamelanotide increases pain-free light exposure in EPP.”
What the sources say: Strong for adult EPP photoprotection when the product and population match Scenesse labeling and EPP trials. Full breakdown
“Afamelanotide is a cosmetic tanning peptide.”
What the sources say: Misleading when stated broadly. The Scenesse evidence is about a rare phototoxic disease, not ordinary cosmetic tanning. Full breakdown
“Scenesse evidence applies to melanotan, research vials, or compounded products.”
What the sources say: No. Scenesse data explain the regulated implant, not unrelated vials or nasal products. Full breakdown
“Afamelanotide has been studied for vitiligo.”
What the sources say: A real positive human signal exists for afamelanotide implants added to NB-UVB, especially in darker skin phototypes. Full breakdown
“The safety profile is simple because Scenesse is approved.”
What the sources say: The label and EPP follow-up literature are the right safety sources, not casual tanning-peptide language. Full breakdown
“AOD-9604 is an established human fat-loss peptide.”
What the sources say: Overstated. There was an early finding, but the larger human obesity trial was negative. Full breakdown
“Injectable AOD-9604 has strong human obesity evidence.”
What the sources say: Current subcutaneous market use is not the same thing as the historical oral and IV studies. Full breakdown
“AOD-9604 repairs cartilage, joints, or muscle in humans.”
What the sources say: No cartilage, joint, muscle-repair, or recovery benefit in humans is documented in these sources. Full breakdown
“AOD-9604 is safe because it is GRAS.”
What the sources say: Misleading when used as a shortcut for therapeutic safety. Full breakdown
“What can a COA tell you about an AOD-9604 vial?”
What the sources say: A COA can be one narrow data point. FDA-reviewed injectable quality also requires sterility, endotoxin, identity, fill, stability, and manufacturing controls. Full breakdown
“BAC water is used to reconstitute peptides.”
What the sources say: Correct as a diluent statement. It says nothing about whether a peptide product, protocol, or seller is safe. Full breakdown
“BAC water is antibacterial medicine.”
What the sources say: BAC water is a preserved diluent, not a treatment. Full breakdown
“BAC water, sterile water, and saline are interchangeable.”
What the sources say: The exact diluent matters. BAC water, sterile water, saline, and bacteriostatic saline change preservative exposure, tonicity, storage assumptions, and whether a vial can be used as multi-dose. Full breakdown
“More BAC water means a stronger peptide.”
What the sources say: Wrong. More diluent lowers concentration; less diluent raises concentration. Full breakdown
“A COA proves a BAC water vial is safe.”
What the sources say: Vendor paperwork matters only when the source, lot, sterility, storage, and handling chain can be tied to the vial in hand. Full breakdown
“Cagrilintide is a weight-loss peptide.”
What the sources say: Cagrilintide is an investigational weight-management candidate, not an approved drug, a basis for self-directed use, or evidence that online products are equivalent to the trial drug. Full breakdown
“Cagrilintide is the same thing as CagriSema.”
What the sources say: Cagrilintide is the single amylin analogue; CagriSema is the combination with semaglutide. Full breakdown
“Online cagrilintide products inherit the clinical-trial evidence.”
What the sources say: The trial data describe controlled development material. Online product claims do not establish identity, quality, or regulatory status. Full breakdown
“Cagrilintide is approved or legally compoundable.”
What the sources say: Available FDA and trial sources do not back approval or routine compounding. It is investigational and outside routine compounding under FDA's stated position. Full breakdown
“Cagrilintide shows that adding amylin to GLP-1 is always better.”
What the sources say: The combination rationale is real. Superiority claims need named trials, comparators, endpoints, and population details. Full breakdown
“CagriSema produces major weight loss.”
What the sources say: Strong as a clinical-trial weight-loss signal. It does not tell you what is inside a clinic blend or research-use vial. Full breakdown
“CagriSema improves blood sugar in type 2 diabetes.”
What the sources say: Supported for studied type 2 diabetes populations; final regulator-reviewed prescribing details are not available yet. Full breakdown
“CagriSema is better than tirzepatide.”
What the sources say: Comparisons with tirzepatide need direct head-to-head evidence and exact trial context. Indirect numbers skip differences in trial design, population, adherence, and comparator dose. Full breakdown
“Gray-market CagriSema is the same as the trial drug.”
What the sources say: Trial evidence covers outcomes in studied settings. Seller paperwork still has to show identity, ratio, sterility, concentration, chain of custody, and legal status. Full breakdown
“CagriSema has settled cardiovascular-outcome benefit.”
What the sources say: Cardiovascular outcomes remain an open question until CagriSema-specific outcomes data report. Full breakdown
“Cerebrolysin helps stroke recovery.”
What the sources say: Discuss it as a contested stroke-recovery drug used in some countries, rather than an established stroke treatment or recovery guarantee. Full breakdown
“Cerebrolysin improves memory or cognition.”
What the sources say: Modest disease-context signals exist, especially in dementia studies, but the evidence does not extend to a general nootropic claim. Full breakdown
“Cerebrolysin treats traumatic brain injury.”
What the sources say: Small TBI studies justify further research, but they are not enough to establish routine treatment benefit. Full breakdown
“Cerebrolysin is safe because it is used overseas.”
What the sources say: Short-term tolerability looks acceptable in many trials, but safety still varies across different populations, products, doses, and supply channels. Full breakdown
“A Cerebrolysin vial from an online seller is equivalent to the studied product.”
What the sources say: Product identity is a major issue. A familiar name or COA still needs manufacturer, batch, packaging, storage, and ampoule-format evidence before it can be compared with trial material. Full breakdown
“CJC-1295 no DAC raises growth hormone and IGF-1.”
What the sources say: Plausible endocrine mechanism, but no modern no-DAC clinical outcome result. Full breakdown
“It burns fat, builds muscle, or improves body composition.”
What the sources say: This is popular extrapolation and marketing, not a measured no-DAC result. Full breakdown
“It improves sleep, recovery, skin, joints, or anti-aging.”
What the sources say: Describe these as clinic, vendor, and online claims until direct no-DAC outcome studies are available. Full breakdown
“No-DAC is simply the safer or more natural version of CJC-1295.”
What the sources say: Shorter acting does not automatically mean safer. The safety question remains open. Full breakdown
“A CJC-1295 no-DAC vial with a COA matches the research.”
What the sources say: Lot paperwork can start the check, but it still has to connect the vial to the right molecule, concentration, sterility, endotoxin control, and injectable-product handling. Full breakdown
“The blend builds muscle or improves body composition.”
What the sources say: This is a real market use case, but the cited human studies do not measure lean mass, fat loss, strength, or physique outcomes for the finished blend. Full breakdown
“It improves sleep, recovery, injury healing, or anti-aging.”
What the sources say: Common in clinic and user discussion. The cited studies explain why the idea exists, but they do not measure sleep, recovery, injury-healing, or aging outcomes for the finished blend. Full breakdown
“The no-DAC CJC component can borrow CJC-1295 DAC trial results.”
What the sources say: DAC data are a weak proxy for a no-DAC blend because the CJC exposure, companion peptide, and product identity are different. Full breakdown
“Ipamorelin has established clinical efficacy for broad use.”
What the sources say: Accurate wording is narrow: ipamorelin can stimulate GH acutely in human pharmacology work; broader claims need outcome-specific trials. Full breakdown
“Vendor purity or a COA makes the injectable product safe.”
What the sources say: A single purity claim does not answer the injection questions: sterility, endotoxin, concentration, impurities, aggregation, storage, and whether both blend components are present at the stated amounts. Full breakdown
“Desmopressin is an approved prescription peptide drug.”
What the sources say: True only when the exact product, route, indication, and label are named. The approval stays with those labeled products; it does not cover wellness, nootropic, gray-market, or research-use product claims. Full breakdown
“Desmopressin is helpful for nocturia or bedwetting.”
What the sources say: Supported for defined labeled populations and products. It is not a general sleep aid or convenience drug. Full breakdown
“Desmopressin is a memory or nootropic peptide.”
What the sources say: Best described as weak, mixed, investigational cognition evidence. It is too weak for a memory-enhancer claim. Full breakdown
“Desmopressin is safe because it is just a peptide analog.”
What the sources say: No; desmopressin is a clinically useful drug with clinically important electrolyte risk. Full breakdown
“Seller paperwork or a research-use listing makes desmopressin equivalent to an approved product.”
What the sources say: For desmopressin, lot paperwork or a research-use listing still leaves the decisive questions open: finished-dose accuracy, route-device performance, sterility, and lawful supply. Full breakdown
“DMSO is an approved drug.”
What the sources say: True only when the product and indication are named. It is not a blanket approval for every DMSO product or use. Full breakdown
“DMSO can be used as a transdermal carrier for peptides.”
What the sources say: The RIMSO-50 label describes bladder instillation only; it does not evaluate topical peptide delivery or DMSO-as-carrier claims. Full breakdown
“DMSO treats urinary infections.”
What the sources say: The approved product use is symptom relief in interstitial cystitis, not bacterial infection treatment. Full breakdown
“Any DMSO product is comparable.”
What the sources say: Not comparable without product-specific quality and route information. RIMSO-50 evidence is about that specific bladder-irrigation product. Full breakdown
“DMSO is harmless because it is just a solvent.”
What the sources say: That framing is too casual. Even the narrow labeled use carries practical safety and monitoring issues. Full breakdown
“Epitalon improves sleep.”
What the sources say: Reasonable as a circadian-biomarker hypothesis. Overstated when presented as a sleep-efficacy claim. Full breakdown
“Epitalon is a longevity peptide.”
What the sources say: Useful for discussing the mechanism. Too thin for an anti-aging or lifespan-treatment claim. Full breakdown
“Epitalon regulates circadian rhythm.”
What the sources say: Reasonable as a biomarker-based circadian discussion. It is not the same thing as a treatment for a diagnosed circadian disorder. Full breakdown
“Epitalon and Pinealon are one combined sleep stack.”
What the sources say: Epitalon and Pinealon are different molecules with different claims. Combining the names does not make the stack a tested timing or dosing approach. Full breakdown
“Epitalon is safe because some studies reported no side effects.”
What the sources say: Safety confidence is low, especially for compounded or research-market injectable products. Full breakdown
“Follistatin-315 builds muscle in healthy adults.”
What the sources say: Easy to understand as a search theme, but retail Follistatin-315 still lacks healthy-adult outcome data. Full breakdown
“The human studies show follistatin works for muscle disease.”
What the sources say: The disease-study evidence is relevant background, but it is small, investigational, and not direct support for commercial FST315 use. Full breakdown
“Retail Follistatin-315 vials match endogenous FS315.”
What the sources say: A product name alone cannot show that the material matches endogenous FS315. Full breakdown
“Follistatin is only a myostatin blocker.”
What the sources say: The myostatin-only explanation is incomplete. Systemic follistatin biology reaches beyond muscle. Full breakdown
“A purity percentage or COA settles the quality question.”
What the sources say: Not enough. Identity, full-length structure, glycosylation, potency, sterility, endotoxin, and lot-specific testing matter. Full breakdown
“Follistatin-344 is a clinically established muscle-building peptide.”
What the sources say: The supported claim is narrower: small disease gene-transfer studies are worth discussing, but gray-market Follistatin-344 is not a clinically established muscle-building peptide. Full breakdown
“It works by blocking myostatin.”
What the sources say: Directionally true as a mechanism headline, but too narrow if it implies a clean, myostatin-only effect. Full breakdown
“A research vial is equivalent to the clinical-study material.”
What the sources say: Retail FS344 claims require evidence that the material is the intended biologic and has been characterized well enough to compare with the gene-transfer literature; a matching name is insufficient. Full breakdown
“It is safe because the small trials reported few problems.”
What the sources say: Small disease studies did not reveal major short-term problems, while broader gray-market use remains poorly characterized and has a serious ocular warning. Full breakdown
“Follistatin gene therapy improves body composition or aging markers.”
What the sources say: Mentionable as sponsor-linked market activity, not as an established benefit. Full breakdown
“Gonadorelin helps ovulation or fertility in GnRH-deficient settings.”
What the sources say: Most credible when the claim stays tied to GnRH deficiency, specialist assessment, and pump-style study regimens. Much weaker when applied to general wellness or broad hormone optimization. Full breakdown
“Gonadorelin boosts testosterone naturally.”
What the sources say: Plausible biology, but not broad evidence of testosterone optimization. The best-supported context remains specialist reproductive endocrinology. Full breakdown
“Gonadorelin preserves fertility or testicular size during TRT.”
What the sources say: Commonly discussed, but the pump literature is a poor match for intermittent TRT-adjunct schedules. Full breakdown
“Gonadorelin is basically hCG.”
What the sources say: Related conversation, different pharmacology. Treating gonadorelin as a drop-in hCG replacement overstates the current evidence. Full breakdown
“Gonadorelin is a GH secretagogue, fat-loss, muscle-gain, or anti-aging peptide.”
What the sources say: Wrong category for GH claims, and weak support for fat-loss, muscle, or anti-aging claims. Full breakdown
“The blend seals or repairs the gut barrier.”
What the sources say: Larazotide is the component with the real human gut evidence; the full BPC-157 + KPV + larazotide stack still has not shown gut-barrier repair in humans. Full breakdown
“It treats Crohn's disease or ulcerative colitis.”
What the sources say: Crohn's and ulcerative-colitis mentions should be treated as marketing and regulatory-risk examples, not as evidence that the blend works for IBD. Full breakdown
“It helps IBS, gut cramps, or broad digestive discomfort.”
What the sources say: IBS and gut-cramp claims are market context unless they are tied to a tested product, population, and endpoint. Full breakdown
“It has clinically tested ingredients.”
What the sources say: The clinically studied ingredient is larazotide; that evidence does not establish the commercial capsule blend. Full breakdown
“What can a COA or purity claim tell you?”
What the sources say: A COA is product paperwork. Finished-product quality also depends on identity, peptide amounts, dissolution, contaminants, stability, packaging, and storage. Full breakdown
“IGF-1 DES produces targeted muscle growth where it is injected.”
What the sources say: "Local growth" is the market phrase. Human site-specific hypertrophy evidence was not found. Full breakdown
“IGF-1 DES is about 10 times stronger than native IGF-1.”
What the sources say: Reasonable only as a lab-model potency statement. It is not a human dose conversion or expected muscle-gain result. Full breakdown
“IGF-1 DES can build muscle, cause hyperplasia, or speed recovery.”
What the sources say: Mechanistically understandable and common in bodybuilding discussion, but still built mostly from preclinical work and anecdotes. Full breakdown
“The short half-life makes it safer than longer-acting IGF analogs.”
What the sources say: A short half-life is not the same as lower risk. Full breakdown
“Vendor COAs make IGF-1 DES research vials reliable.”
What the sources say: A COA can be a clue, but pharmaceutical-grade sterility, correct concentration, and clinical comparability need more than a narrow purity document. Full breakdown
“IGF-1 LR3 is clinically established for muscle growth.”
What the sources say: Overstated. The support is mostly mechanism and market interest, not a direct human muscle-building result for LR3. Full breakdown
“LR3 is just a longer-lasting version of IGF-1.”
What the sources say: Too simple. LR3 is meaningfully different from native IGF-I, but the common long-half-life claim compresses several different pharmacology questions into one marketing line. Full breakdown
“LR3 helps recovery, tendons, repair, or injuries.”
What the sources say: Plausible biology, but direct human repair outcomes for tendons, joints, and injuries were not found in the cited LR3 material. Full breakdown
“LR3 supports fat loss, recomp, nutrient partitioning, or anti-aging.”
What the sources say: Mostly extrapolation from mechanism and market positioning. The evidence explains why these claims exist, but it does not show that LR3 produces those benefits in people. Full breakdown
“A vendor COA makes an LR3 vial equivalent to a regulated product.”
What the sources say: A COA may describe a submitted batch. The practical risk is the vial in hand: whether it is sterile, potency-accurate, sequence-confirmed, and suitable for injection needs separate proof. Full breakdown
“Ipamorelin raises growth hormone.”
What the sources say: Supported for a short-term hormone response. That finding is not a promised clinical outcome. Full breakdown
“Ipamorelin causes fat loss or body recomposition.”
What the sources say: Overstated. The marketed promise is much stronger than the available human outcome evidence. Full breakdown
“Ipamorelin improves sleep, recovery, anti-aging, collagen, or cognition.”
What the sources say: These are clinic-marketing and anecdotal-use themes. The cited ipamorelin studies do not measure those benefits. Full breakdown
“Subcutaneous ipamorelin protocols are already settled.”
What the sources say: Subcutaneous use is common in the market, but the IV human studies do not define that use pattern. Route-specific human data remain a major gap. Full breakdown
“A COA or purity percentage proves an ipamorelin vial matches study material.”
What the sources say: A COA can be one limited data point. For an injectable product, the unresolved pieces are sterility, endotoxin, potency, storage, delivered dose, and traceability to the exact lot. Full breakdown
“Kisspeptin-10 acutely stimulates LH and the reproductive axis.”
What the sources say: Reasonable for a narrow acute hormone-signaling statement. Too weak for routine hormone-treatment use. Full breakdown
“Kisspeptin-10 raises testosterone.”
What the sources say: More accurately, this is a hormone-signaling hypothesis with limited human data, not a TRT alternative or testosterone therapy. Full breakdown
“Kisspeptin-10 helps fertility, puberty, or hypogonadotropic hypogonadism.”
What the sources say: The stronger statement stays with research and diagnostic interest unless stronger outcome trials are added. Full breakdown
“Kisspeptin-10 improves libido or sexual wellness.”
What the sources say: A common market theme, not a supported KP-10 use. Full breakdown
“A research-use or compounded KP-10 vial is equivalent to study material.”
What the sources say: Product quality needs to be read separately from KP-10 pharmacology. Full breakdown
“KLOW works for recovery, healing, or injury repair.”
What the sources say: KLOW is a repair-themed blend. Calling it an injury-healing or recovery product would require blend-level human outcomes, not just component logic. Full breakdown
“KLOW reduces inflammation or helps gut and immune problems.”
What the sources say: The biology explains why KLOW is marketed for inflammation, but no human KLOW study shows improvement in gut, immune, or inflammatory outcomes. Full breakdown
“KLOW improves skin quality, wrinkles, or radiance.”
What the sources say: The skin rationale is the most understandable part of the blend, but a KLOW vial has not been shown to reproduce topical GHK-Cu study outcomes. Full breakdown
“KLOW helps hair growth.”
What the sources say: Hair claims mostly come from GHK-Cu extrapolation and blend marketing, not tested KLOW outcomes. Full breakdown
“What can a public COA say about a KLOW vial?”
What the sources say: A COA can support a narrow batch claim. For a mixed peptide vial, sterility, per-peptide content, stability, and handling need to be checked product by product. Full breakdown
“KPV treats ulcerative colitis, Crohn's disease, or gut inflammation.”
What the sources say: Reasonable to describe as preclinical gut-inflammation biology. Turning that into a human IBD treatment or gut-healing protocol would need human exposure and outcome data. Full breakdown
“KPV helps with skin inflammation, barrier repair, or wound healing.”
What the sources say: Skin and wound claims can be mentioned as market and mechanism themes, but no demonstrated KPV skin or wound protocol was found. Full breakdown
“KPV has antimicrobial effects.”
What the sources say: Discussable as laboratory antimicrobial biology, not as an infection-treatment claim. Full breakdown
“Oral KPV is a ready-to-use gut protocol.”
What the sources say: Oral delivery is still a research problem here. The human evidence does not provide a ready-to-use protocol. Full breakdown
“KPV is safe because it is short and derived from alpha-MSH.”
What the sources say: The safety picture is thin because human exposure data, route-specific tolerability, and finished-product quality evidence are missing. Full breakdown
“L-carnitine is a mitochondrial support compound.”
What the sources say: Useful as a mechanism description. General wellness outcomes need direct evidence. Full breakdown
“L-carnitine injections are a fat-loss or body-composition protocol.”
What the sources say: The CARNITOR label does not establish a fat-loss, cutting, or cosmetic body-composition regimen. Full breakdown
“The CARNITOR label gives practical dose patterns.”
What the sources say: Useful label information, but not a wellness or gym-use regimen. Full breakdown
“Oral L-carnitine and injectable L-carnitine are interchangeable.”
What the sources say: Too simple. Product, route, formulation, and use context need to be named before the claim means anything. Full breakdown
“L-carnitine is harmless because it is naturally occurring.”
What the sources say: Misleading as a safety shortcut. The route, amount, product, patient context, and interacting drugs matter. Full breakdown
“LL-37 fights bacteria, fungi, viruses, and biofilms.”
What the sources say: The preclinical host-defense rationale is real, but it has not shown human treatment benefit for infections, Lyme, mold illness, SIBO, or biofilm eradication. Full breakdown
“LL-37 helps chronic wounds or skin repair.”
What the sources say: Discussable as topical investigational wound research. Not a general skin repair, infection, or injectable recovery claim. Full breakdown
“LL-37 boosts immunity.”
What the sources say: A general immune-boosting claim is too broad. LL-37 immune biology is mixed, route-specific, and sometimes inflammatory. Full breakdown
“LL-37 works as a general injectable wellness peptide.”
What the sources say: The injectable human evidence belongs to the melanoma research context. Clinic and forum claims do not provide a general injection pattern. Full breakdown
“LL-37 is safe because the body makes it.”
What the sources say: Natural origin does not remove formulation, route, sterility, endotoxin, immune activation, reproductive, or tumor-biology concerns. Full breakdown
“Melanotan-1 is the same as afamelanotide.”
What the sources say: The alias is real; product equivalence is not. The name can point toward afamelanotide, but it does not make a non-approved Melanotan-1 product equivalent to Scenesse. Full breakdown
“Melanotan-1 improves sun tolerance or photoprotection.”
What the sources say: Valid for regulated Scenesse use in EPP. It is not general photoprotection or a sunscreen substitute. Full breakdown
“Melanotan-1 is a safer tanning peptide than Melanotan-2.”
What the sources say: The real distinction is approved Scenesse versus non-approved melanotan-market products; that distinction is not evidence for a safer cosmetic tanning option. Full breakdown
“Scenesse evidence applies to research vials or compounded Melanotan-1.”
What the sources say: Using the afamelanotide name still leaves formulation, release, stability, and monitoring evidence to be documented. Full breakdown
“Melanotan-1/afamelanotide has human evidence in vitiligo.”
What the sources say: There is a positive human signal for controlled afamelanotide implants added to NB-UVB, but vitiligo is not a current approved indication. Full breakdown
“It darkens skin or increases tanning.”
What the sources say: There is a real pigmentation finding, but the evidence is too limited and the market too unreliable to treat MT-II as a safe tanning product. Full breakdown
“It boosts libido or erections.”
What the sources say: The finding is credible enough to mention, but the evidence does not make gray-market MT-II a general libido or sexual-performance product. Full breakdown
“It helps appetite control or weight loss.”
What the sources say: Appetite effects can be discussed as a possible melanocortin effect, but reliable MT-II weight-loss efficacy has not been shown. Full breakdown
“It replaces sunscreen or protects against skin cancer.”
What the sources say: No. TGA specifically warns against relying on melanotan products instead of sun protection, and FDA enforcement material treated skin-cancer and rosacea claims as unlawful promotion. Full breakdown
“A vendor COA makes the vial safe.”
What the sources say: A COA is a narrow sample document. For MT-II, product identity and finished-product controls matter as much as the pharmacology. Full breakdown
“Methylene blue treats acquired methemoglobinemia.”
What the sources say: Accurate only when stated as the labeled acquired-methemoglobinemia use for PROVAYBLUE or another appropriate medical methylene blue product. Full breakdown
“Methylene blue is a nootropic.”
What the sources say: Discussable as a market claim, but not as a PROVAYBLUE-label benefit. Full breakdown
“Methylene blue supports mitochondria and redox balance.”
What the sources say: The redox mechanism is real; broad mitochondrial wellness claims remain outside the PROVAYBLUE label. Full breakdown
“All methylene-blue products are interchangeable.”
What the sources say: Product identity and route are the risk. A prescription IV solution, a lab dye, an aquarium product, and an oral-drop bottle can share a color while carrying very different impurity, concentration, and exposure problems. Full breakdown
“The main safety issue is just blue urine or staining.”
What the sources say: The interaction and monitoring issues matter more than the color novelty. Full breakdown
“N-Acetyl Semax Amidate improves focus, memory, or motivation.”
What the sources say: People do talk about it as a Semax-family nootropic. The exact analogue still lacks human outcome data in the cited sources. Full breakdown
“It raises BDNF in people.”
What the sources say: Parent-Semax BDNF findings can explain why the analog is marketed this way, but they do not show BDNF changes or cognitive benefit for Ac-Semax-NH2. Full breakdown
“It is just Semax but stronger, longer acting, or more bioavailable.”
What the sources say: This remains a hypothesis until exact-variant human exposure data exist. Full breakdown
“A 99% purity COA verifies a current vial or spray.”
What the sources say: Incomplete. A purity number is useful only as one small part of product-quality evidence. Full breakdown
“It is an FDA-approved or clinically accepted Semax product.”
What the sources say: The cited sources do not identify it as an FDA-approved or clinically accepted U.S. Semax product. Full breakdown
“Pinealon improves cognition or protects the brain.”
What the sources say: Worth discussing as a neurobiology topic, but direct cognition and neurorecovery outcome evidence is still limited. Full breakdown
“Pinealon improves sleep quality or REM sleep.”
What the sources say: A narrow historical sleep-symptom signal exists, but it is too limited to call Pinealon a sleep treatment or to support as-needed use patterns. Full breakdown
“Pinealon has a standard cycle or repeat-course protocol.”
What the sources say: The concrete pattern is the old oral report. Newer cycle claims remain unverified claims rather than a settled schedule. Full breakdown
“Pinealon and Epitalon are a supported stack.”
What the sources say: Pinealon and Epitalon need separate evaluation. The chemistry and study history support distinction, not a stack recommendation. Full breakdown
“A Pinealon label settles the product-identity issue.”
What the sources say: Product quality has to be evaluated separately from the EDR literature and the label name. Full breakdown
“Retatrutide causes major weight loss.”
What the sources say: Supported for studied clinical-trial populations. Online products sold as RETA need evidence of the vial contents and how the product was handled. Full breakdown
“Retatrutide is better than tirzepatide or semaglutide.”
What the sources say: Superiority is not established. Current comparisons are indirect until head-to-head evidence or regulator-reviewed comparative data exist. Full breakdown
“Retatrutide improves blood sugar.”
What the sources say: Supported in studied type 2 diabetes populations; final regulatory labeling is not available yet. Full breakdown
“Gray-market RETA is the same as trial retatrutide.”
What the sources say: No. Trial data describe Lilly's study drug; a retail vial needs separate proof of identity, handling, and quality. Full breakdown
“Retatrutide is already an approved medicine.”
What the sources say: An approval claim needs a current FDA label, EMA EPAR, or comparable authorization document. Full breakdown
“Semaglutide has approved-product data for type 2 diabetes.”
What the sources say: Strong for approved diabetes products; it does not cover every oral, compounded, or research-use semaglutide product. Full breakdown
“Semaglutide has approved-product data for weight management.”
What the sources say: Strong for Wegovy-labeled use; weaker or off-label when the same statement is about Ozempic, Rybelsus, compounded vials, or online sellers. Full breakdown
“A compounded semaglutide vial is basically the same as Wegovy or Ozempic.”
What the sources say: No. Ingredient-name overlap does not make a compounded vial equivalent to an FDA-reviewed pen, syringe, or tablet. Full breakdown
“Compounded semaglutide dosing is easy to copy from a pen label.”
What the sources say: High risk. FDA's warning is specifically about compounded injectable products and dose-measurement mistakes. Full breakdown
“Online semaglutide sellers can be judged by price or a COA.”
What the sources say: Price, website polish, and a posted COA do not establish authenticity, potency, microbiology, endotoxin control, degradation, labeling, or storage conditions. Full breakdown
“Sermorelin helps growth-hormone-deficient children grow.”
What the sources say: A legitimate historical pediatric claim, not a broad modern adult performance or anti-aging claim. Full breakdown
“Sermorelin can be used to test GH reserve.”
What the sources say: Historically real for GH reserve testing, but separate from current adult diagnostic-tool choice. Full breakdown
“Sermorelin is an anti-aging or longevity peptide.”
What the sources say: The adult evidence is exploratory. The market claims are much broader. Full breakdown
“Sermorelin is helpful for weight loss, fat loss, or body recomposition.”
What the sources say: Commonly marketed, weakly supported for exact Sermorelin, and easily confused with tesamorelin. Full breakdown
“Research-use vials or compounded Sermorelin are equivalent to Geref.”
What the sources say: No; a shared molecule name is not the same as a current product matching a historical regulated drug product. Full breakdown
“The blend raises endogenous growth hormone.”
What the sources say: The mechanism makes sense. The combined product still needs direct human measurement before the GH-response claim can be treated like component data. Full breakdown
“Sermorelin + ipamorelin improves body composition or fat loss.”
What the sources say: Common in the market, but not measured for the combined product in the cited human studies. Full breakdown
“It improves sleep, recovery, vitality, or anti-aging.”
What the sources say: Real-world use is common; controlled human benefit data for the blend are still missing. Full breakdown
“It is safer than human growth hormone because it is more natural.”
What the sources say: The "natural" safety shortcut is misleading. Route, dose, duration, endocrine monitoring, and product quality still matter. Full breakdown
“A clinic vial or vendor COA makes the blend equivalent to studied material.”
What the sources say: Mechanism alone cannot show whether a blend vial has the right identity, ratio, sterility, or injectable quality. Full breakdown
“Setmelanotide is FDA-approved for weight management.”
What the sources say: Accurate only for Imcivree inside the label. It becomes misleading when used as a blanket claim for ordinary obesity, wellness weight loss, peptide stacks, or non-approved setmelanotide products. Full breakdown
“Setmelanotide treats ordinary obesity.”
What the sources say: The label points to rare-disease obesity care, not general obesity or cosmetic fat-loss use. Full breakdown
“The POMC, PCSK1, and LEPR pathway data are strong.”
What the sources say: Strong for the named rare pathway-deficiency setting, weak as support for broader weight-loss claims. Full breakdown
“Setmelanotide has Bardet-Biedl syndrome evidence.”
What the sources say: Supported for BBS-specific chronic weight management under the Imcivree label, not for unrelated syndromic obesity or broad weight-loss use. Full breakdown
“Research-market setmelanotide is equivalent to Imcivree.”
What the sources say: The generic name is not the product. Imcivree evidence comes from a labeled 10 mg/mL sterile vial, defined storage, rare-disease selection, and monitored clinical use. Full breakdown
“TB-500 repairs tendons, ligaments, or muscle.”
What the sources say: TB-500 is widely marketed and discussed for recovery, but TB-500-specific support is still mostly identity work and preclinical biology. Full breakdown
“TB-500 has the same evidence as full-length thymosin beta-4.”
What the sources say: Keep TB-500 fragment, full-length thymosin beta-4, and blend products separate because each can involve a different molecule, route, exposure, and product-quality question. Full breakdown
“A TB-500 vial has a known human dose or cycle.”
What the sources say: The cited material does not give a controlled standalone human TB-500 regimen. Full breakdown
“TB-500 has a human wound-healing mechanism.”
What the sources say: Say "preclinical wound-activity evidence," not human wound-healing evidence. Full breakdown
“Product testing or a COA makes TB-500 safe to inject.”
What the sources say: Not enough. A COA can be one document to inspect, but it is not finished injectable safety or human-benefit evidence. Full breakdown
“Tesamorelin reduces visceral belly fat.”
What the sources say: Best supported for HIV-associated visceral abdominal fat. General belly-fat or cosmetic cutting talk usually extrapolates from that data. Full breakdown
“Tesamorelin causes general weight loss.”
What the sources say: Better described as a visceral-fat and body-composition claim than a general weight-loss claim. Full breakdown
“Tesamorelin may improve liver fat.”
What the sources say: The liver-fat finding comes from HIV-related studies using a specific route, dose, duration, and population. Full breakdown
“Tesamorelin is an anti-aging, recovery, or sleep peptide.”
What the sources say: These are off-label extrapolations. The cited market examples show timing and body-composition programs, not direct human evidence for sleep, recovery, or anti-aging. Full breakdown
“Research-use or gray-market tesamorelin is equivalent to Egrifta.”
What the sources say: The name tesamorelin does not show whether a vial is Egrifta-like, sterile, correctly concentrated, stored correctly, or monitored like the products used in trials. Full breakdown
“Thymosin beta-4 helps heal the ocular surface.”
What the sources say: Plausible and supported by the best human evidence, but still investigational and route-specific. Full breakdown
“Thymosin beta-4 works for tendon, muscle, or training-injury recovery.”
What the sources say: Overstated. The claim is common online, but the available human evidence is too narrow for it. Full breakdown
“TB-500 has the same evidence as full-length thymosin beta-4.”
What the sources say: Full-length Tbeta4 evidence does not establish the effects of TB-500 fragments or market products. Eye-drop and topical-wound studies do not support claims for an injected recovery vial. Full breakdown
“Thymosin beta-4 has human chronic-wound evidence.”
What the sources say: Reasonable to mention as limited investigational wound evidence, not as evidence of broad systemic healing. Full breakdown
“Thymosin beta-4 is safe because it occurs naturally in the body.”
What the sources say: Too simple. Safety depends on molecule, route, duration, product quality, and patient context. Full breakdown
“Tirzepatide is an approved weight-loss drug.”
What the sources say: Strong for labeled Zepbound use and tirzepatide-specific trials; much weaker when the same claim is made for compounded or gray-market products. Full breakdown
“Tirzepatide improves blood sugar in type 2 diabetes.”
What the sources say: Strong for Mounjaro's labeled type 2 diabetes use and for named tirzepatide trials. Full breakdown
“Tirzepatide treats sleep apnea.”
What the sources say: Strong for Zepbound's labeled OSA population; it does not make tirzepatide a general sleep aid. Full breakdown
“Tirzepatide prevents type 2 diabetes.”
What the sources say: Promising and substantial for the studied group, but it has not become an FDA-labeled diabetes-prevention claim. Full breakdown
“A compounded or COA-backed tirzepatide product matches Zepbound or Mounjaro.”
What the sources say: Same-active-ingredient wording is only one piece. Formulation, labeling, manufacturing, device, storage, oversight, and efficacy still have to line up. Full breakdown
“The blend heals tendons, ligaments, muscle, or joints.”
What the sources say: Too broad as a clinical claim. Wolverine Blend is a repair-themed market product built on indirect component evidence. Full breakdown
“How much does BPC-157 evidence tell us about the blend?”
What the sources say: BPC-157 explains why the blend is discussed, but the commercial blend still needs direct human outcome data. Full breakdown
“Can thymosin beta-4 evidence be applied to TB-500?”
What the sources say: Keep TB-500 fragment and full-length thymosin beta-4 separate. Blending the names together is one of the easiest ways to make the product sound more proven than it is. Full breakdown
“The blend is safe if a vendor posts purity or a COA.”
What the sources say: A COA can be one document to inspect, but the exact vial would still need lot-linked identity, per-component assay, sterility, endotoxin, stability, and chain-of-custody support. Full breakdown
“Wolverine Blend is a legal supplement or approved therapy.”
What the sources say: Legal supplement or approved-therapy claims go beyond the current evidence. Full breakdown
“Adamax is marketed as a longer-acting Semax.”
What the sources say: Marketed as longer-acting Semax, but the cited material does not show a measured human duration advantage. Full breakdown
“Adamax improves focus, motivation, or brain fog.”
What the sources say: Focus and motivation claims show up often in Adamax marketing and forum reports, but they are not measured Adamax effects. Full breakdown
“Parent Semax evidence carries over to Adamax.”
What the sources say: Parent Semax provides background. It does not tell you Adamax's efficacy, duration, dose, or safety profile. Full breakdown
“A COA or purity number makes Adamax trustworthy.”
What the sources say: A purity number is a start, not a full answer on identity or route-specific quality for the route someone intends. Full breakdown
“The GHK-Cu + KPV blend is established for skin rejuvenation.”
What the sources say: This is a popular skin and repair blend, but it is not an established skin-rejuvenation treatment. Full breakdown
“KPV makes the blend an inflammation or gut-health treatment.”
What the sources say: The available support is preclinical rationale plus market discussion, not evidence for a gut or immune treatment. Full breakdown
“The blend is a better repair peptide because the ingredients are synergistic.”
What the sources say: The pairing is plausible enough to study, but human synergy has not been demonstrated. Full breakdown
“A research-use vial with a COA solves the quality question.”
What the sources say: COA language can provide limited batch information. Sterile injectable quality, correct concentration for both peptides, endotoxin control, copper-complex integrity, and blend stability require batch-specific… Full breakdown
“Myostatin propeptide is a clinically established human muscle builder.”
What the sources say: Overstated. The stronger claim is target biology and preclinical activity, with no direct human efficacy study found for the named product. Full breakdown
“Less myostatin automatically means better strength and performance.”
What the sources say: Too simple. Muscle size is not the only endpoint, and performance claims need human outcome data that this product does not have. Full breakdown
“Animal studies support interest in muscle, fracture, regeneration, and metabolism.”
What the sources say: Reasonable to discuss as preclinical rationale. Too early for human therapy language. Full breakdown
“Research-use labels or certificates make gray-market products reliable.”
What the sources say: A certificate is only a narrow quality clue. For this category, a paperwork claim and a product that matches the studied construct are different things. Full breakdown